The effect of acarbose on the pharmacokinetics of rosiglitazone

European Journal of Clinical Pharmacology

Volumn 57, Issue 2, 2001, Pages 105-109

  Miller, Ann K ^a   Inglis, Anne Marie ^b   Culkin, Kathleen Thompson ^b   Jorkasky, Diane K ^b   Freed, Martin I ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

Acarbose; Pharmacokinetic interaction; Rosiglitazone

Indexed keywords

ACARBOSE; ROSIGLITAZONE;

ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TIME;

ACARBOSE; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0035034146     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280100275     Document Type: Conference Paper

References (28)

1. 1. Cantello BCC, Cawthorne MA, Haigh D, Hindley RM, Smith SA, Thurlby PL (1997) The synthesis of BRL 49653 - a novel and potent antihyperglycaemic agent. Bioorg Med Chem Lett 4:1181-1184
2. 2. Smith SA, Boam D, Cawthorne MA (1998) Rosiglitazone improves insulin sensitivity and reduces hyperexpression of insulin and amylin mRNAa in pancreatic islets (abstract 0365). Diabetes 47 [Suppl 1]:A94
3. 3. Grunberger G, Weston WM, Patwardhan R, et al (1999) Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes (abstract 0439). Diabetes 48 [Suppl 1]:A102
4. 4. Patel J, Anderson RJ, Rappaport EB (1999) Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1:165-172
5. 5. Nolan JJ, Jones NP, Patwardhan R, Deacon LF (2000) Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes. Diabet Med 17:287-294
6. 6. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI (2000) Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes. Diabetologia 43:278-284
7. 7. Charbonnel B, Lonnqvist F, Jones NP, Martin G, Abel MG, Patwardhan R (1999) Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 year of treatment in type 2 diabetic patients (abstract 0494). Diabetes 48 [Suppl 1]:A114
8. 8. Fonseca V, Rappaport EB, Salzman A, Patwardhan R (2000) Once-daily rosiglitazone in combination with metformin effectively reduces hyperglycemia in patients with type 2 diabetes. JAMA 283:1695-1702
9. 9. Wollfenbuttel BHR, Gomis R, Squandrito S, Jones NP, Patwardhan RN (2000) Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetes patients. Diabet Med 17:40-47
10. 10. Raskin P, Dole JF, Rappaport EB (1999) Rosiglitazone improves glycemic control in poorly controlled insulin-treated type 2 diabetes (abstract 0404). Diabetes 48 [Suppl 1]:A94
11. 11. Cox PJ, Ryan DA, Hollis FJ, et al (2000) Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 28:772-780
12. 12. Bolton GC, Keogh JP, East PD, Hollis FJ, Shore AD (1996) The fate of a thiazolidinedione antidiabetic agent in rat and dog. Xenobiotica 26:627-636
13. 13. Amatruda JM (1996) α-Glucosidase inhibitors in the treatment of diabetes. In: LeRoith D, Taylor SI, Olefsky JM (eds) Diabetes mellitus: a fundamental and clinical text. Lippincott-Raven, Philadelphia, pp 643-646
14. 14. Campbell LK, White JR, Campbell RK (1996) Acarbose: its role in the treatment of diabetes mellitus. Ann Pharmacother 30:1255-1262
15. 15. Martin AE, Montgomery PA (1996) Acarbose: an alphaglucosidase inhibitor. Am J Health Syst Pharm 53:2277-2290
16. 16. Yee HS, Fong NT (1966) A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy 16:792-805
17. 17. Clissold SP, Edwards C (1988) Acarbose, a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35:214-243
18. 18. Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T, Lefebvre PJ (1994) Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 24 [Suppl 3]:50-54
19. 19. Ahr HJ, Boberg M, Krause HP (1989) Pharmacokinetics of acarbose. 1. Absorption, concentration in plasma, metabolism and excretion after single administration of (14C) acarbose to rats, dogs and man. Arzneimittelforschung 39:1254-1260
20. 20. Hagel J, Ruppin H, Pichl J (1985) α-Glucosidase inhibitor acarbose, fate and effects in man. Gastroenterology 88:1410
21. 21. Salvatore T, Giugliano D (1996) Pharmacokinetic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet 30:94-106
22. 22. Freed MI, Allen A, Jorkasky DK, DiCicco RA (1999) Systemic exposure to rosiglitazone is unaltered by food. Eur J Clin Pharmacol 55:53-56
23. 23. Muxlow AM, Fowles S, Russell P (2001) Automated high performance liquid chromatography method for the determination of rosiglitazone in human plasma. J Chromatogr B 752:77-84
24. 24. Mertes G (1998) Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. Diabetes Res Clin Pract 40:63-70
25. 25. Ben-Ami H, Krivoy N, Nagachandran P, Roguin A, Edoute Y (1999) An interaction between digoxin and acarbose (letter). Diabetes Care 22:860-861
26. 26. Serrano JS, Jimenez CM, Serrano MI, Balboa B (1996) A possible interaction of potential clinical interest between digoxin and acarbose. Clin Pharmacol Ther 60:589-592
27. 27. Morreale AP, Janetzky K (1997) Probable interaction of warfarin and acarbose (letter). Am J Health Syst Pharm 54:1551-1552
28. 28. Baldwin SJ, Clarke SE, Chenery RJ (1999) Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48:424-432